13.43
price down icon0.81%   -0.11
after-market After Hours: 13.00 -0.43 -3.20%
loading
Avalo Therapeutics Inc stock is traded at $13.43, with a volume of 6,141. It is down -0.81% in the last 24 hours and up +37.49% over the past month. Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$13.54
Open:
$13.23
24h Volume:
6,141
Relative Volume:
0.24
Market Cap:
$124.65M
Revenue:
$1.93M
Net Income/Loss:
$-31.54M
P/E Ratio:
-6.2757
EPS:
-2.14
Net Cash Flow:
$-30.68M
1W Performance:
-1.25%
1M Performance:
+37.49%
6M Performance:
-6.48%
1Y Performance:
+12,901%
1-Day Range:
Value
$12.85
$13.50
1-Week Range:
Value
$11.98
$13.60
52-Week Range:
Value
$0.0333
$34.46

Avalo Therapeutics Inc Stock (AVTX) Company Profile

Name
Name
Avalo Therapeutics Inc
Name
Phone
410-522-8707
Name
Address
540 GAITHER ROAD, ROCKVILLE
Name
Employee
19
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
AVTX's Discussions on Twitter

Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-24-21 Initiated RBC Capital Mkts Outperform

Avalo Therapeutics Inc Stock (AVTX) Latest News

pulisher
Oct 26, 2024

Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated at HC Wainwright - Defense World

Oct 26, 2024
pulisher
Oct 15, 2024

When (AVTX) Moves Investors should Listen - Stock Traders Daily

Oct 15, 2024
pulisher
Oct 08, 2024

Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Avalo Therapeutics maintains Outperform rating from Oppenheimer - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Avalo Therapeutics begins Phase 2 trial for hidradenitis suppurativa By Investing.com - Investing.com UK

Oct 08, 2024
pulisher
Oct 08, 2024

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial - GlobeNewswire

Oct 08, 2024
pulisher
Oct 08, 2024

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - Yahoo Finance

Oct 08, 2024
pulisher
Oct 08, 2024

Ikarian Capital, LLC Adjusts Stake in Avalo Therapeutics Inc - GuruFocus.com

Oct 08, 2024
pulisher
Oct 05, 2024

(AVTX) Technical Pivots with Risk Controls - Stock Traders Daily

Oct 05, 2024
pulisher
Sep 27, 2024

Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 38.1% - Defense World

Sep 27, 2024
pulisher
Sep 25, 2024

Avalo Therapeutics: Pioneering Biotech Solutions for Immune Disorders - The China Perspective

Sep 25, 2024
pulisher
Sep 25, 2024

Affinity Asset Advisors LLC Acquires 35,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Where are the Opportunities in (AVTX) - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Purchases New Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World

Sep 24, 2024
pulisher
Sep 13, 2024

How To Trade (AVTX) - Stock Traders Daily

Sep 13, 2024
pulisher
Sep 10, 2024

Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.8% - Defense World

Sep 10, 2024
pulisher
Sep 04, 2024

Avalo Therapeutics regains Nasdaq compliance - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Avalo Announces Participation in September Investor Conferences - GlobeNewswire

Sep 04, 2024
pulisher
Sep 02, 2024

Financial Health Report: Avalo Therapeutics Inc (AVTX)’s Ratios Tell a Tale - The Dwinnex

Sep 02, 2024
pulisher
Aug 29, 2024

Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily

Aug 29, 2024
pulisher
Aug 19, 2024

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July - Defense World

Aug 19, 2024
pulisher
Aug 18, 2024

Avalo Therapeutics (FRA:C6K0) Cash From Discontinued Investing Activities : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 15, 2024

Oppenheimer sees upside in Avalo Therapeutics stock as phase 2 trial nears - Investing.com

Aug 15, 2024
pulisher
Aug 14, 2024

Avalo Therapeutics (NASDAQ:AVTX) Releases Earnings Results - Defense World

Aug 14, 2024
pulisher
Aug 13, 2024

Avalo Therapeutics sees cash runway into 2027 - TipRanks

Aug 13, 2024
pulisher
Aug 12, 2024

AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024 - InvestorPlace

Aug 12, 2024
pulisher
Aug 12, 2024

Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - citybiz

Aug 12, 2024
pulisher
Aug 09, 2024

Avalo Therapeutics Inc expected to post a loss of $6.70 a shareEarnings Preview - XM

Aug 09, 2024
pulisher
Jul 28, 2024

Natixis Lowers Stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World

Jul 28, 2024
pulisher
Jul 26, 2024

(AVTX) Long Term Investment Analysis - Stock Traders Daily

Jul 26, 2024
pulisher
Jul 24, 2024

The 3 Best Personalized Nutrition Stocks to Buy Now - InvestorPlace

Jul 24, 2024
pulisher
Jul 24, 2024

Avalo Therapeutics (NASDAQ:AVTX) Shares Down 2.1% - Defense World

Jul 24, 2024
pulisher
Jul 16, 2024

Avalo Therapeutics welcomes new Chief Medical Officer - Investing.com

Jul 16, 2024
pulisher
Jul 16, 2024

Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma

Jul 16, 2024
pulisher
Jul 16, 2024

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewswire Inc.

Jul 16, 2024
pulisher
Jul 09, 2024

Avalo Therapeutics begins Phase 2 trial for HS treatment By Investing.com - Investing.com South Africa

Jul 09, 2024
pulisher
Jul 09, 2024

Avalo Therapeutics begins Phase 2 trial for HS treatment - Investing.com

Jul 09, 2024
pulisher
Jul 09, 2024

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa - GlobeNewswire

Jul 09, 2024
pulisher
Jul 06, 2024

(AVTX) Technical Data - Stock Traders Daily

Jul 06, 2024
pulisher
Jul 02, 2024

Avalo Therapeutics Names Seasoned Pharma Atty As CLO - Law360

Jul 02, 2024
pulisher
Jul 01, 2024

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Decrease in Short Interest - Defense World

Jul 01, 2024
pulisher
Jun 27, 2024

Form DEFA14A Avalo Therapeutics, Inc. - StreetInsider.com

Jun 27, 2024
pulisher
Jun 25, 2024

Avalo Therapeutics appoints new Chief Legal Officer By Investing.com - Investing.com Australia

Jun 25, 2024
pulisher
Jun 25, 2024

Avalo Therapeutics Appoints Paul Varki as Chief Legal Officer - citybiz

Jun 25, 2024
pulisher
Jun 25, 2024

Avalo Therapeutics appoints new Chief Legal Officer - Investing.com India

Jun 25, 2024
pulisher
Jun 25, 2024

Matson CEO Cox sells over $1m in company stock By Investing.com - Investing.com

Jun 25, 2024

Avalo Therapeutics Inc Stock (AVTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):